by Osteogenesis imperfecta also known as brittle bone disease affects the connective tissues, primarily the bones, resulting in easy fracturing. The major symptoms include fragile and brittle bones that break easily from minor trauma or with little force. Treatment of osteogenesis imperfecta currently focuses on both pharmacological and supportive therapies to improve bone strength, reduce fractures, and manage pain. Bisphosphonates are commonly prescribed to reduce fractures and increase bone density. Recombinant human bone morphogenetic protein-2 or BMP-2 is also approved to increase bone formation. Advances in gene therapies and therapies targeting the underlying genetic defects offer hope to effectively treat this condition.
The global osteogenesis imperfecta treatment market is estimated to be valued at US$ 832.67 million in 2024 and is expected to exhibit a CAGR of 4.2% over the forecast period 2024-2031, as highlighted in a new report published by Coherent Market Insights.
The market is driven by the development of advanced treatment options such as PTC’s Translarna gene therapy, Sangamo’s SB-913 gene therapy, and Astellas Pharma’s vadadustat targeting the underlying causes of brittle bone disease. These novel drug candidates are anticipated to receive regulatory approvals over the coming years and transform the treatment landscape.
Market Key Trends:
One of the key trends in the osteogenesis imperfecta treatment market is the growing research and development for gene therapy and molecular targeted therapies. Gene therapy aims to introduce a corrected copy of the defective COL1A1/COL1A2 genes to restore normal type I collagen synthesis. Notable companies developing gene therapies include Astellas Pharma with AT132 for non-synonymous COL1A1/COL1A2 mutations, and Sangamo Therapeutics with ST-920 (ZXN-8220) targeting COL1A1 splicing mutations. PTC Therapeutics’ Translarna (ataluren) acts by read-through of premature termination codons and is approved in Europe for nonsense mutation cases. Vadadustat under development by Akebia/Astellas inhibits hypoxia-inducible factor and stabilizes HIF, thereby enhancing endogenous Epo levels and bone formation. These advanced treatment options hold potential to effectively treat the underlying cause of brittle bone disease.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate due to high capital requirements and need for regulatory approvals. However, growing prevalence of osteogenesis imperfecta is encouraging new players to enter the market.
Bargaining power of buyers: The bargaining power of buyers is low as treatment of osteogenesis imperfecta is necessary. However, availability of generic drugs provides some bargaining power.
Bargaining power of suppliers: The bargaining power of suppliers is high due to specialized manufacturing needs and fewer suppliers. This allows suppliers to influence prices.
Threat of new substitutes: There is no substitute currently available for treating osteogenesis imperfecta. Research on new drug candidates may introduce new substitutes in future.
Competitive rivalry: The osteogenesis imperfecta treatment market includes few large players holding major share. Intense competition exists between players to gain higher market share through product launches and partnerships.
Key Takeaways
The global Osteogenesis Imperfecta Treatment Market Share is expected to witness high growth. The global osteogenesis imperfecta treatment market is estimated to be valued at US$ 832.67 million in 2024 and is expected to exhibit a CAGR of 4.2% over the forecast period 2024-2031.
The North America osteogenesis imperfecta treatment market is expected to dominate during the forecast period. This is attributed to high diagnosis and treatment rates in the region. Asia Pacific market is anticipated to grow at fastest rate due to increasing healthcare expenditure.
Key players related content comprisesa
Key players operating in the Osteogenesis Imperfecta Treatment market are AmSurg Corp., HCA Holdings, Inc., Tenet Healthcare, Surgical Care Affiliates, Inc., Surgery Partners, Ambulatory Surgical Centers of America, Heathway Medical Group, Community Health Systems, Inc., and Vision Group Holdings. Growing prevalence of osteogenesis imperfecta and launch of newer drugs and therapies are encouraging these players to invest in R&D. Partnerships with research institutes are also adopted by players to develop advanced treatment options.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
